Sep 2026· The Egyptian Journal of Internal Medicine· Vol 38· 0 citations· 23 references
TL;DR
It is proposed that C-peptide has evolved from a fibrosis biomarker to a mechanistic node and actionable target and routine integration into metabolic screening could enhance early risk stratification and monitoring of therapies modulating hyperinsulinemia.
Abstract
Metabolically-dysfunction-associated steatotic liver disease (MASLD), the leading chronic liver condition worldwide, is driven by hyperinsulinemia and insulin resistance, with C-peptide serving as a stable marker of endogenous insulin secretion. In this perspective, we propose to redefine C-peptide as an active driver rather than a passive marker in MASLD pathogenesis. In our July 2025 cross-sectional study of 118 participants, we demonstrated that elevated serum C-peptide independently signals fibrosis risk in obese patients with MASLD, showing moderate correlation with the non-alcoholic fatty liver disease (NAFLD) Fibrosis Score, acceptable discriminatory performance (AUC 0.75 at cut-off 1.78 ng/mL), and a linear relationship in regression modelling. Subsequent studies from late 2025 to early 2026 have advanced this foundation. Refined indices, such as the fasting C-peptide/HDL-C ratio (FHR) and HOMA2 IR-CP, exhibit nonlinear associations and superior predictive accuracy for MASLD in type 2 diabetes. Recently, C-peptide has been identified as a primary causal driver of hepatic steatosis, independent of peripheral resistance. We propose that C-peptide has evolved from a fibrosis biomarker to a mechanistic node and actionable target. Routine integration into metabolic screening could enhance early risk stratification and monitoring of therapies modulating hyperinsulinemia. The relatively small sample size of our cross-sectional cohort need more studies on larger scale. C-peptide deserves further study as a possible biomarker in future prospective trials validating its role in MASLD pathophysiology.
In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin res...
Eddison Godinez Leiva, Diana Barb, S. Kalavalapalli et al.· Diabetologia· 0 citations
Clinicians should consider screening lean individuals with metabolic risk factors even when BMI is within the normal range even when BMI is within the normal range, as a pragmatic and clinically reasonable first step can be used for the early identification and prevention of complications.
Mohammad Abu Faisal, S. Hasan· Discover medicine· 0 citations
Roughly 90% of patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) have at least one feature of metabolic syndrome, a disease characterized by insulin resistance, obesity, hypertension and hyperlipidemia. MASLD can be accessed by the Enhanced Liver Fibrosis test (ELF, Siemens Healthinee...
C. Orahoske, Shirley Li, Alan H. B. Wu· Clinical Chemistry· 0 citations
Paired liver and VAT biopsies are profiled to identify distinct sex-associated transcriptional states in liver and VAT in MASLD and show that these states are coordinated across both tissues within the same individuals.
Mijra Koning, I. Hu, A. Kovynev et al.· bioRxiv· 0 citations
BACKGROUND
Insulin resistance (IR) plays a pathophysiological role in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear whether the specific distribution of IR across muscle, adipose tissue, hepatic tissue, and the whole body is associated with the heteroge...
Long Teng, Ling Luo, Cong-Xiang Shao et al.· Journal of the American Nutr...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.